Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

Y0001018

Cisplatin impurity A

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

trans-Platinum(II)diammine dichloride, trans-Diamminedichloroplatinum(II), trans-Dichlorodiammineplatinum(II)

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
Pt(NH3)2Cl2
CAS Number:
14913-33-8
Molecular Weight:
300.05
MDL number:
MFCD00011623
UNSPSC Code:
41116107
PubChem Substance ID:
329831221
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

cisplatin

manufacturer/tradename

EDQM

mp

340 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cisplatin impurity A EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Related product

Product No.
Description
Pricing

C2210000

Cisplatin, European Pharmacopoeia (EP) Reference Standard

Y0001019

Cisplatin impurity B, European Pharmacopoeia (EP) Reference Standard

1551300

Potassium Trichloroammineplatinate, United States Pharmacopeia (USP) Reference Standard

1672803

Transplatin, United States Pharmacopeia (USP) Reference Standard

1134357

Cisplatin, United States Pharmacopeia (USP) Reference Standard

PHR1624

Cisplatin, Pharmaceutical Secondary Standard; Certified Reference Material

BP809

Cisplatin, British Pharmacopoeia (BP) Reference Standard

BP510

Potassium trichloroammineplatinate, British Pharmacopoeia (BP) Reference Standard

BP544

Transplatin, British Pharmacopoeia (BP) Reference Standard

PHR3252

Transplatin, pharmaceutical secondary standard, certified reference material

pictograms

Health hazardCorrosion
GHS08,GHS05

signalword

Danger

Hazard Classifications

Eye Dam. 1 - Resp. Sens. 1 - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

James Chih-Hsin Yang et al.
The Lancet. Oncology, 16(2), 141-151 (2015-01-16)
We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Previously untreated patients with EGFR mutation-positive stage IIIB or IV
Xi-Chun Hu et al.
The Lancet. Oncology, 16(4), 436-446 (2015-03-22)
Platinum chemotherapy has a role in the treatment of metastatic triple-negative breast cancer but its full potential has probably not yet been reached. We assessed whether a cisplatin plus gemcitabine regimen was non-inferior to or superior to paclitaxel plus gemcitabine
Koichi Azuma et al.
Oncotarget, 5(15), 5908-5919 (2014-08-15)
Most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, but the clinical efficacy of EGFR-TKIs is limited by the appearance of drug resistance. Multiple kinase inhibitors of EGFR family proteins such as afatinib have been newly developed to
Yuniardini S Wimardhani et al.
Journal of oral science, 56(2), 119-126 (2014-06-17)
Chitosan, a multipurpose biomaterial, has been shown to exert effects against several types of cancer including oral cancer. However, the mechanisms underlying the anticancer activities of chitosan on oral squamous cell carcinoma (SCC) cells remain largely unknown. The present study
Vicente Fresquet et al.
Blood, 123(26), 4111-4119 (2014-05-03)
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service